Next-Generation Biomanufacturing Market Research Report Information By Type (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, and Downstream Biomanufacturing), By Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins and Others), By End-User (Biopharmaceutical Companies, Research Institutions and CMOs/CDMOs) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Next-Generation Biomanufacturing Market Overview

Next-Generation Biomanufacturing Market Size was valued at USD 23.1 Billion in 2022. The Next-Generation Biomanufacturing market industry is projected to grow from USD 25.4 Billion in 2023 to USD 54.0 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.90% during the forecast period (2024 - 2032). The growing prevalence of chronic diseases, the expanding pipeline of biopharmaceutical drugs, and the rising adoption of personalized medicine are the key market drivers that are enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Next-Generation Biomanufacturing Market Trends

• Growing demand for biologics is driving the market growth

Market CAGR for Next-Generation Biomanufacturing is being driven by the increasing demand for biologics. Biologics, including monoclonal antibodies, vaccines, and cell therapies, are widely used in the treatment of various diseases, such as cancer, autoimmune disorders, and infectious diseases. As the prevalence of these diseases rises and new therapeutic targets are identified, the demand for biologics continues to grow. Next-generation biomanufacturing technologies offer advantages such as increased efficiency, scalability, and flexibility compared to traditional manufacturing methods, enabling biopharmaceutical companies to meet the growing demand for biologics more effectively. Additionally, advancements in bioprocessing technologies, such as continuous manufacturing and single-use systems, enable faster production cycles and reduce costs, further driving the adoption of next-generation biomanufacturing solutions.

Increasing investment in research and development (R&D) is a significant driver of the Next-Generation Biomanufacturing Market. Biopharmaceutical companies, academic institutions, and government agencies are allocating substantial resources to R&D efforts aimed at developing innovative biologics and improving biomanufacturing processes. The growing demand for advanced therapies, personalized medicine, and novel drug modalities, such as gene and cell therapies, drives this investment. Next-generation biomanufacturing technologies, including continuous processing, automation, and digitalization, offer opportunities to enhance efficiency, productivity, and quality in biologics manufacturing. By investing in these technologies, organizations aim to streamline production processes, reduce manufacturing costs, and accelerate time-to-market for new biologic products, driving the growth of the Next-Generation Biomanufacturing Market.

Advanced bioprocessing technologies are a key driver of the Next-Generation Biomanufacturing Market. These technologies, such as continuous manufacturing, single-use systems, and automation, offer several advantages over traditional methods, including increased efficiency, flexibility, and scalability. Continuous manufacturing allows for uninterrupted production, leading to shorter processing times, higher yields, and reduced costs. Single-use systems eliminate the need for cleaning and validation between batches, saving time and resources. Automation improves process control, reproducibility, and data integrity, enhancing overall manufacturing performance.

Additionally, advanced bioprocessing technologies enable the production of complex biologics, including gene and cell therapies, which require precise control over manufacturing conditions. As biopharmaceutical companies seek to improve productivity, reduce costs, and accelerate time-to-market for new therapies, the adoption of advanced bioprocessing technologies continues to drive the growth of the Next-Generation Biomanufacturing Market. For instance, Thermo Fisher Scientific unveiled the CE-IVD-marked Ion Torrent Genexus Dx Integrated Biomanufacturing, an automated next-generation Biomanufacturing (NGS) platform designed to provide results within a single day. Such advancements are responsible for raising the overall next-generation biomanufacturing market revenue.

Next-Generation Biomanufacturing Market Segment Insights

• 
  

  Next-Generation Biomanufacturing Type Insights

  
  

The Next-Generation Biomanufacturing Market segmentation, based on type, includes Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, and Downstream Biomanufacturing. In 2023, the Continuous Upstream Biomanufacturing segment dominated the market, accounting for 35% of market revenue due to several factors. Firstly, continuous processes offer advantages such as increased productivity, reduced manufacturing footprint, and improved product quality compared to traditional batch processes. Secondly, continuous upstream biomanufacturing enables real-time monitoring and control, leading to enhanced process efficiency and consistency. Lastly, the scalability and flexibility of continuous processes make them well-suited for meeting the growing demand for biologics and accommodating changing production requirements in the biopharmaceutical industry.

Single-Use Upstream Biomanufacturing is experiencing the highest Compound Annual Growth Rate (CAGR) in the Next-Generation Biomanufacturing Market due to several factors. Firstly, single-use systems offer advantages such as reduced risk of contamination, lower capital investment, and increased flexibility compared to traditional stainless-steel systems. Secondly, the scalability and adaptability of single-use technologies make them well-suited for the production of diverse biologics, including monoclonal antibodies, vaccines, and cell therapies. Lastly, the rising adoption of single-use systems by biopharmaceutical companies and contract manufacturing organizations (CMOs) drives market growth.

• 
  

  Next-Generation Biomanufacturing Application Insights

  
  

The Next-Generation Biomanufacturing Market segmentation, based on Application, includes Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, and Others. In 2023, The Monoclonal Antibodies category generated the most income. mAbs are widely used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, driving significant demand for their production. Secondly, advancements in bioprocessing technologies, such as continuous manufacturing and single-use systems, have improved the efficiency and scalability of mAb production, making them a preferred choice for biopharmaceutical companies. Lastly, the increasing adoption of personalized medicine approaches further fuels demand for mAbs, contributing to their dominant market position in next-generation biomanufacturing.

Hormone application is experiencing the highest Compound Annual Growth Rate (CAGR) in the Next-Generation Biomanufacturing Market due to several factors. Firstly, there is increasing demand for hormone-based therapies in areas such as endocrinology, reproductive health, and oncology. Secondly, advancements in bioprocessing technologies enable more efficient and cost-effective production of hormones, driving their adoption in biomanufacturing processes. Lastly, the expanding application of hormones in personalized medicine and the treatment of hormonal disorders further accelerates market growth.

• 
  

  Next-Generation Biomanufacturing End-User Insights

  
  

The Next-Generation Biomanufacturing Market segmentation, based on End-User, includes Biopharmaceutical Companies, Research Institutions, and CMOs/CDMOs. In 2023, The Biopharmaceutical Companies category generated the most income. Biopharmaceutical companies are the primary drivers of innovation and development in the biomanufacturing industry, continuously seeking to enhance production efficiency and product quality. Secondly, the increasing demand for biologic drugs, including monoclonal antibodies, vaccines, and cell therapies, further fuels the adoption of next-generation biomanufacturing technologies by these companies. Lastly, the scalability and flexibility of these technologies meet the evolving needs of biopharmaceutical manufacturers, driving their widespread adoption.

Research institution's end-user segment is experiencing the highest Compound Annual Growth Rate (CAGR) in the Next-Generation Biomanufacturing Market due to several factors. Firstly, research institutions are increasingly investing in advanced biomanufacturing technologies to support academic research, development of novel therapies, and bioprocess optimization. Secondly, collaborations between academia and industry foster the adoption of next-generation biomanufacturing solutions in research settings. Lastly, the growing emphasis on translational research and personalized medicine drives demand for innovative bioprocessing technologies in academic laboratories.

Figure 1: Next-Generation Biomanufacturing Market, by End-User, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Next-Generation Biomanufacturing Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the Next-Generation Biomanufacturing Market due to several factors. Firstly, the region has a strong presence of biopharmaceutical companies, academic institutions, and research organizations driving innovation and adoption of advanced biomanufacturing technologies. Secondly, supportive regulatory frameworks and robust healthcare infrastructure facilitate market growth. Lastly, the presence of key market players, strategic collaborations, and high investment in research and development contribute to North America's leading position in the Next-Generation Biomanufacturing Market.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: NEXT-GENERATION BIOMANUFACTURING MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Next-Generation Biomanufacturing market accounts for the second-largest market share due to the collaborations between industry and academia. Europe secures the second largest market share in the Next-Generation Biomanufacturing Market due to several factors. Firstly, the region boasts a strong biopharmaceutical industry with a focus on innovation and adoption of advanced biomanufacturing technologies. Secondly, supportive regulatory policies and initiatives promote the development and commercialization of next-generation biomanufacturing solutions. Additionally, collaborations between industry and academia, coupled with significant investments in research and development, contribute to Europe's position as a key player in the Next-Generation Biomanufacturing Market. Further, the German Next-Generation Biomanufacturing market held the largest market share, and the UK Next-Generation Biomanufacturing market was the fastest-growing market in the European region.

The Asia-Pacific Next-Generation Biomanufacturing Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia-Pacific region is experiencing the highest Compound Annual Growth Rate (CAGR) in the Next-Generation Biomanufacturing Market due to several factors. Firstly, the region's growing population and increasing healthcare expenditure drive demand for biologics and advanced biomanufacturing technologies. Secondly, rising investments in biotechnology research and development, coupled with supportive government initiatives, foster innovation and adoption of next-generation biomanufacturing solutions. Additionally, the presence of a skilled workforce, expanding biopharmaceutical industry, and strategic collaborations contribute to the rapid growth of the Next-Generation Biomanufacturing Market in Asia-Pacific. Moreover, China’s Next-Generation Biomanufacturing market held the largest market share, and the Indian Next-Generation Biomanufacturing market was the fastest-growing market in the Asia-Pacific region.

Next-Generation Biomanufacturing Key Market Players & Competitive Insights

Leading players in the Next-Generation Biomanufacturing Market are actively engaged in strategic initiatives to maintain their competitive edge. This includes investing in research and market developments to develop innovative biomanufacturing technologies, enhancing manufacturing capabilities, and expanding product portfolios. Additionally, companies are focusing on strategic collaborations, partnerships, and acquisitions to strengthen their market presence, accelerate product development, and expand into new geographic regions. Continuous innovation, quality assurance, and customer-centric approaches are key strategies employed by leading players to drive growth in the Next-Generation Biomanufacturing Market.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Next-Generation Biomanufacturing industry to benefit clients and increase the market sector. In recent years, the Next-Generation Biomanufacturing industry has offered some of the most significant advantages to monoclonal antibodies. Major players in the Next-Generation Biomanufacturing market, including Illumina Inc., Thermo Fischer Scientific Inc., Oxford Nanopore Technologies plc, Agilent Technologies, Inc., BGI, PerkinElmer Inc., QIAGEN, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Takara Bio Inc., and Others, are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc. is a leading global provider of scientific instruments, reagents, consumables, software, and services for research, healthcare, and applied markets. In the Next-Generation Biomanufacturing Market, Thermo Fisher Scientific offers a comprehensive portfolio of bioprocessing solutions tailored to meet the evolving needs of biopharmaceutical manufacturers. This includes advanced bioreactor systems, single-use technologies, chromatography systems, purification solutions, and analytics tools. With a focus on innovation, quality, and customer satisfaction, Thermo Fisher Scientific collaborates closely with biopharmaceutical companies to accelerate bioprocess development, improve manufacturing efficiency, and ensure product quality. Through continuous investment in research and development, strategic acquisitions, and global expansion, Thermo Fisher Scientific remains at the forefront of shaping the future of biomanufacturing.

Oxford Nanopore Technologies plc is a UK-based biotechnology company specializing in the development of innovative nanopore sequencing technology. In the Next-Generation Biomanufacturing Market, Oxford Nanopore Technologies offers disruptive solutions for real-time DNA and RNA sequencing, enabling rapid and accurate analysis of biological samples. Their portable and scalable sequencing platforms, such as the Minion and Prom ethion systems, empower researchers and biopharmaceutical companies to perform on-site sequencing, process monitoring, and quality control during biomanufacturing processes. By providing accessible and versatile sequencing tools, Oxford Nanopore Technologies revolutionizes biomanufacturing workflows, enabling faster decision-making, improved process optimization, and enhanced product quality assurance. Through ongoing innovation and collaboration, the company continues to drive advancements in next-generation biomanufacturing technologies.

Key Companies in the Next-Generation Biomanufacturing market include

• Illumina Inc.


• Thermo Fischer Scientific Inc.


• Oxford Nanopore Technologies plc


• BGI (China)


• PerkinElmer Inc.


• QIAGEN


• Eurofins Scientific


• Agilent Technologies, Inc.


• Hoffmann-La Roche Ltd


• Takara Bio Inc.

Next-Generation Biomanufacturing Industry Developments

January 2023: QIAGEN disclosed a strategic collaboration with Helix, a population genomics leader based in California, to propel next-generation sequencing companion diagnostics in hereditary diseases.

September 2022: Illumina Inc. introduced the NovaSeq X Series, comprising the NovaSeq X and NovaSeq X Plus, representing new production-scale next-generation sequencers designed to facilitate quicker, more robust, and environmentally sustainable sequencing.

Next-Generation Biomanufacturing Market Segmentation

Next-Generation Biomanufacturing Type Outlook

• Continuous Upstream Biomanufacturing


• Single-Use Upstream Biomanufacturing


• Downstream Biomanufacturing

Next-Generation Biomanufacturing Application Outlook

• Monoclonal Antibodies


• Hormones


• Vaccines


• Recombinant Proteins


• Others

Next-Generation Biomanufacturing End-User Outlook

• Biopharmaceutical Companies


• Research Institutions


• CMOs/CDMOs

Next-Generation Biomanufacturing Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America